Information Provided By:
Fly News Breaks for August 18, 2015
OMER
Aug 18, 2015 | 13:16 EDT
Wedbush raised Omeros' price target to $70 from $61 following the announcement of positive data in the OMS721 Phase II clinical trial. The firm expects a launch of OMS721 in aHUS in mid 2018 and conservatively estimates gross peak sales of over $900M. Wedbush also considers Omeros a future takeout target dn reiterates its Outperform rating.
News For OMER From the Last 2 Days
There are no results for your query OMER
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.